BioCentury
ARTICLE | Tools & Techniques

Trinity identifies hurdles for tissue-agnostic therapies

May 22, 2018 10:56 PM UTC

While the use of basket trials to test therapies in tissue agnostic, biomarker-based cancer indications is increasing, the long-term implications rely on a handful of factors, many of which may affect postmarket uptake of agents approved via this route, according to a white paper from Trinity Partners (Waltham, Mass.) published Tuesday.

For example, tissue-agnostic therapies would often require next-generation sequencing to identify patients with the mutations studied in basket trials. Universal testing for rare biomarkers may receive pushback from payers due to costs and the biomarkers may not be included in commonly used NGS panel. ...